Michael Braun: The Work Is Not Finished in Sickle Cell Disease
Michael Braun, U.S. Specialty Care President at Pfizer, shared a post on LinkedIn:
“Sickle cell disease affects millions of people worldwide — and still carries the weight of inequity. For too many, the journey is defined not just by pain and crises, but by delayed diagnoses, limited access to specialized care, and treatment options that haven’t kept pace with the urgency.
On World Sickle Cell Day, I’m thinking about a community that has been asked to wait too long for progress — and what it means to truly show up for them.
For our team at Pfizer, that means continuing to advance our research and education in sickle cell disease, supporting scholarships, helping nonprofit organizations in their mission to ease the burden of travel to care, and listening closely to the people most affected.
Progress is possible, and it’s also necessary. Our work isn’t finished.
To everyone living with sickle cell, caring for someone who is, or fighting for change in this community:
Stay updated with Hemostasis Today.
-
Jun 20, 2026, 19:51Sushmita Sen: How are We Doing in Global Clinical Trials and Precision Hematology?
-
Jun 20, 2026, 19:46Rainer Kaiser: How Neutrophils Stiffen Thrombi in Acute Ischemic Stroke
-
Jun 20, 2026, 19:38Muhammad Amjad Sohail: Stroke – Recognize the Signs, Save a Life
-
Jun 20, 2026, 19:36Osman Eladani: How Do We Optimize Bleeding Risk Management in Elective Surgery?
-
Jun 20, 2026, 19:26Abdul Mannan: Pregnancy Changes Almost Every Coagulation Test
-
Jun 20, 2026, 19:24Rubi Stephani Hellwege: Why Two Patients With the Same Cardiac Output Can Be Completely Different
-
Jun 20, 2026, 19:20Alexander Cohen: How Long Should You Treat VTE?
-
Jun 20, 2026, 19:11Ayesha Masood: Delighted to Share My First Published Meta-Analysis
-
Jun 20, 2026, 18:56Registration Closing Tonight – 3rd Antithrombotic Stewardship Summit at ISTH 2026 – Anticoagulation Forum